46 completed, 16 terminated, 5 unknown, 2 active not recruiting. 70 Phase 1, 20 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 70 | Completed 46, Terminated 16, Unknown 5, Active not recruiting 2, Withdrawn 1 |
| Phase 2 | 20 | Completed 12, Unknown 4, Terminated 3, Withdrawn 1 |
Follow Recurrent Adult Diffuse Large Cell Lymphoma: new trials by email Literature Review of Recurrent Adult Diffuse Large Cell Lymphoma trials Research Report on Recurrent Adult Diffuse Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 anti-CD19/22-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-08-01 | 2019-04-17 |
| Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 anti-CD19/20-CAR vector-transduced T cells - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 100 | 2017-04-01 | 2020-09-02 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients Retroviral vector-transduced autologous T cells to express CD22-specific CARs - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Unknown | Xinqiao Hospital of Chongqing | 20 | 2016-03-01 | 2017-03-10 |
| Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma anti-CD19 CAR-T, Fludarabine, Cyclophosphamide - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine | 20 | 2016-02-01 | 2017-03-16 |
| Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma CD19.CAR-T cells - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Unknown | Xinqiao Hospital of Chongqing | 20 | 2015-12-01 | 2019-02-27 |
| Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Selinexor, Ibrutinib, Pharmacological Study - Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 1 | Completed | Jennifer Woyach | 34 | 2015-06-09 | 2025-06-10 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride, rituximab - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia | Phase 1 | Terminated | Wake Forest University Health Sciences | 1 | 2014-12-01 | 2018-07-02 |
| Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer everolimus, bendamustine hydrochloride - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 1 | Completed | University of California, Davis | 20 | 2014-10-01 | 2019-01-04 |
| Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study - Adult B Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 72 | 2014-09-01 | 2015-08-20 |
| Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma BTK inhibitor PCI-32765, rituximab, bendamustine hydrochloride - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Active not recruiting | Kami Maddocks, MD | 48 | 2014-03-26 | 2026-07-22 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, autologous hematopoietic stem cell transplantation, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 30 | 2013-10-08 | 2026-06-25 |
| Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Central Nervous System Lymphoma | Phase 1 | Completed | Mayo Clinic | 29 | 2013-04-08 | 2019-07-22 |
| Ipilimumab and Local Radiation for Selected Solid Tumors Ipilimumab, Radiation therapy - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Stanford University | 3 | 2013-02-01 | 2024-01-24 |
| Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy anti-CD20-CAR vector-transduced autologous T cells, genetically engineered lymphocyte therapy - Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 50 | 2013-01-01 | 2015-09-29 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant allogeneic cytomegalovirus-specific cytotoxic T lymphocytes - Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 1 | 2012-04-01 | 2017-02-15 |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies therapeutic allogeneic lymphocytes - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Phase 1 | Completed | Robert Lowsky | 16 | 2012-01-01 | 2023-11-22 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
Showing 20 of 70. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (70) · Lymphoma, Mantle-Cell (67) · Lymphoma, Follicular (64) · Leukemia, Lymphocytic, Chronic, B-Cell (58) · Lymphoma, B-Cell, Marginal Zone (53) · Burkitt Lymphoma (52) · Lymphoma, Non-Hodgkin (49) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (49) · Lymphoma, Large-Cell, Immunoblastic (45) · Waldenstrom Macroglobulinemia (45) · Hodgkin Disease (37) · Mycosis Fungoides (33) · Sezary Syndrome (33) · Lymphoma, Large-Cell, Anaplastic (32) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (32)
Hemic and Lymphatic Diseases (70) · Immune System Diseases (70) · Immunoproliferative Disorders (70) · Lymphatic Diseases (70) · Lymphoma (70) · Lymphoproliferative Disorders (70) · Neoplasms by Histologic Type (70) · Lymphoma, B-Cell (69) · Neoplasms (69) · Hematologic Diseases (64) · Leukemia (61) · Leukemia, Lymphoid (61) · Disease Attributes (59) · Pathologic Processes (59) · Pathological Conditions, Signs and Symptoms (59)
Rituximab (12) · Bortezomib (6) · Bendamustine Hydrochloride (5) · fludarabine phosphate (5) · tanespimycin (5) · Carboplatin (4) · Lenalidomide (4) · Peripheral Blood Stem Cell Transplantation (4) · Vorinostat (4) · CTLA-4 Antigen (3) · Cyclosporine (3) · Etoposide (3) · Everolimus (3) · Indium (3) · Ipilimumab (3)
National Cancer Institute (NCI) (37) · Fred Hutchinson Cancer Center (6) · Mayo Clinic (5) · Chinese PLA General Hospital (3) · City of Hope Medical Center (3) · Case Comprehensive Cancer Center (2) · University of Washington (2) · Xinqiao Hospital of Chongqing (2) · Amir Mortazavi (1) · Jennifer Woyach (1) · Kami Maddocks, MD (1) · Morphotek (1) · Robert Lowsky (1) · Stanford University (1) · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine (1)
United States (62) · China (6) · Canada (2) · Italy (2) · Germany (1)
Ajay Gopal (4) · Kristie Blum (2) · Patricia LoRusso (2) · Ramesh Ramanathan (2) · Amir Mortazavi, MD (1) · Antonius Miller (1) · Bo Zhu, M.D., Ph.D. (1) · Brenda Cooper (1) · Brenda Sandmaier (1) · Cameron Turtle (1) · Chandra Belani (1) · Charles Erlichman (1) · Colleen Delaney (1) · Craig Reeder, M.D. (1)
PMID 34515338, PMID 32499241, PMID 18974373, PMID 22259028, PMID 23256542, PMID 24241210, PMID 24474568, PMID 24530971, PMID 25317870, PMID 25355819, PMID 25444722, PMID 26853648, PMID 26943915, PMID 27118452, PMID 28270022, PMID 28314788, PMID 29263894, PMID 29292843, PMID 29572391, PMID 30262659, PMID 30562587, PMID 30596402, PMID 31076448, PMID 31388792, PMID 31815579, PMID 32245502, PMID 33492438, PMID 41804087
P30CA015083 (6), P30CA015704 (5), U01CA062487 (5), U01CA062491 (5), U01CA076576 (5), U01CA099168 (5), U01CA062502 (4), U01CA062505 (4), U01CA069912 (3), P01CA044991 (2), P30CA016058 (2), U01CA069852 (2), U01CA121947 (2), U01CA132123 (2), N01CM00070 (1)